Abstract
Background and purpose : There is large variability in the diagnostic approach and clinical management in functional movement disorders (FMD). This study aimed to examine whether opinions and clinical practices related to FMD have changed over the past decade. Methods: Adapted from a 2008 version, we repeated the survey to members of the International Parkinson and Movement Disorder Society (MDS). Results: In all, 864/7689 responses (denominator includes non-neurologists) were received from 92 countries. Respondents were more often male (55%), younger than 45 (65%) and from academic practices (85%). Although the likelihood of ordering neurological investigations prior to delivering a diagnosis of FMD was nearly as high as in 2008 (47% vs. 51%), the percentage of respondents communicating the diagnosis without requesting additional tests increased (27% vs. 19%; P = 0.003), with most envisioning their role as providing a diagnosis and coordinating management (57% vs. 40%; P < 0.001). Compared to patients with other disorders, 64% of respondents were more concerned about missing a diagnosis of another neurological disorder. Avoiding iatrogenic harm (58%) and educating patients about the diagnosis (53%) were again rated as the most effective therapeutic options. Frequent treatment barriers included lack of physician knowledge and training (32%), lack of treatment guidelines (39%), limited availability of referral services (48%) and cultural beliefs about psychological illnesses (50%). The preferred term for communication favored ‘functional’ over ‘psychogenic’ (P < 0.001). Conclusions: Attitudes and management of FMDs have changed over the past decade. Important gaps remain in access to treatment and in the education of neurologists about the inclusionary approach to FMD diagnosis.
Original language | English (US) |
---|---|
Pages (from-to) | 975-984 |
Number of pages | 10 |
Journal | European Journal of Neurology |
Volume | 27 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2020 |
Funding
There are no funding sources to declare for this paper. There are no conflicts of interest pertaining to this paper. Financial disclosures for the previous 12 months are as follows. KL: no relevant disclosures. AEL: has served as an advisor for AbbVie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen, Lilly, Lundbeck, Medtronic, Merck, NeuroPhage Pharmaceuticals, Roche and UCB; received honoraria from AbbVie, the AAN and MDS; received grants from Brain Canada, Canadian Institutes of Health Research, CDB Solutions, Edmond J Safra Philanthropic Foundation, Michael J. Fox Foundation, the Ontario Brain Institute, Parkinson Foundation, Parkinson Society Canada, W. Garfield Weston Foundation; received publishing royalties from Saunders, Wiley‐Blackwell, Johns Hopkins Press and Cambridge University Press; and has served as an expert witness in cases related to the welding industry. JS: receives royalties from UpToDate for articles on functional neurological disorder; runs a free non‐profit self‐help website, www.neurosymptoms.org, and carries out expert witness medicolegal work for personal injury and medical negligence cases involving FMD. FM: has received speaking honoraria from Medtronic, Boston Scientific, Chiesi, AbbVie, Bial, Merz, Zambon; has served on the Advisory Board for Merz UK; received royalties from Springer for the book ; and serves on the Editorial Boards for (Associate Editor) and . ME, SL and CWM: no relevant disclosures. MH: holds patents for an immunotoxin for the treatment of focal movement disorders and the H‐coil for magnetic stimulation; in relation to the latter, he has received licence fee payments from the NIH (from Brainsway); he is on the Medical Advisory Boards of CALA Health, Brainsway and Cadent.; receives royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, Springer and Elsevier; has research grants from Allergan for studies of methods to inject botulinum toxins, Medtronic Inc. for a study of DBS for dystonia, and CALA Health for studies of a device to suppress tremor. AD: supported as a co‐investigator by the NIH (R21 HL143030‐01) and (R21 AI133207) grants and as a collaborator in NIH R21 AI118228 grant; he has also been serving as a statistician in CPRIT grants (PP180003, PP170068, PP170004, and PP130083). Dr Dwivedi is a director of Biostatistics and Epidemiology Consulting Lab at the TTUHSC EP. AJE: has received grant support from the NIH and the Michael J. Fox Foundation; personal compensation as a consultant/scientific advisory board member for AbbVie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press and Springer; and honoraria from USWorldMeds, Acadia and Sunovion. Disorders of Movement Movement Disorders Movement Disorders Clinical Practice
Keywords
- conversion disorder
- functional movement disorders
- psychogenic movement disorders
- survey
ASJC Scopus subject areas
- Clinical Neurology
- Neurology